Validating methylation signatures and variants in pediatric cancer

In this webinar, Danielle Goldberg and Dr. Bodour Salhia will present:

• The chemistry and principles behind Illumina 5-base solution. 
• A head-to-head comparison of DNA methylation profiling using Illumina 5-base solution versus WGBS in pediatric cancers. 
• Evaluation of copy number alterations and single nucleotide variants detected using the 5-base solution. 
• An assessment of whether Illumina 5-base solution can serve as a viable alternative to WGBS. 

Speakers

Danielle Goldberg
Goldberg is a senior manager of product management at Illumina, with over a decade of experience in the genomics industry. She has led the conception through commercialization of multiple microarray and library preparation products. Currently, she is the lead product manager for Illumina’s groundbreaking 5-base solution.

Bodour Salhia, PhD
Associate Professor, Interim Chair, Department of Cancer Biology, Royce and Mary Trotter Chair in Cancer Research, Keck School of Medicine

Bodour Salhia is the inaugural interim chair of the Department of Cancer Biology and the Royce and Mary Trotter Chair in Cancer Research at the Keck School of Medicine of the University of Southern California (USC). She also serves as co-leader of the Epigenetic Regulation in Cancer Program and inaugural director of the Preclinical Models Shared Resource at the USC Norris Comprehensive Cancer Center.

Salhia’s research integrates cell biology, cancer genomics, and epigenomics to address clinically unmet needs. Her primary focus is on developing cfDNA methylation-based liquid biopsy tools for early cancer detection and minimal residual disease (MRD) monitoring. Her team developed OvaPrint, a novel cfDNA methylation assay for early detection of ovarian cancer, and MammaTrace, a tumor-naive liquid biopsy assay for MRD detection in breast cancer.

Salhia earned her bachelor’s degree, master’s degree, and doctorate from the University of Toronto and completed a postdoctoral fellowship in genomics and epigenomics at the Translational Genomics Research Institute. She is the founder of CpG Diagnostics, a precision diagnostics company focused on cfDNA methylation-based technologies for women’s cancers. Salhia also founded the Bench with Bedside Initiative, a direct-to-patient research engagement program, and has led outreach efforts both in the U.S. and abroad.